Health
Experimental Cancer Vaccine Extends Survival in Blood Cancer Trial
Reported by Faizan Khan (Staff Writer) · The Hindu - Health ·

An experimental vaccine named galinpepimut-S, or GPS, helped patients with a fast-growing blood and bone marrow cancer live longer in a late-stage trial, according to Sellas Life Sciences. Patients who received the vaccine lived a median of 24 months, compared to 14.7 months for those who were given the best available treatment.
Next Steps
Sellas Life Sciences plans to talk to the United States Food and Drug Administration about seeking approval for the vaccine. The company's shares were halted in premarket trading following the announcement on Tuesday, November 17, 2026.
Context
Acute myeloid leukaemia is a serious disease that affects the blood and bone marrow, making new treatment options important for patients who face limited choices. Late-stage clinical trials are a key step for drug developers before they can ask health regulators to review a product for public use.
ExplainerWhy this matters
What Happened
Sellas Life Sciences announced that its experimental vaccine, galinpepimut-S or GPS, successfully extended median survival to 24 months in a late-stage trial for patients with acute myeloid leukaemia, compared to 14.7 months for standard treatments.
Why It Matters
Acute myeloid leukaemia is a fast-growing and aggressive cancer of the blood and bone marrow with limited effective treatment choices. A significant increase in overall survival time offers a potential new path forward for patients facing this difficult diagnosis.
What Happens Next
The company will hold discussions with the U.S. Food and Drug Administration to discuss the process for seeking official regulatory approval for the vaccine.
More in Health
HealthSource: Hindustan TimesWorth knowing
Neurologist Explains How Sleep Cycles Work And Why Short Naps Help.
Reported by Abhishek Tiwari (Copy Editor) · Hindustan Times - Health ·
